Drugs / NA17-A
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00036816 | Feb 2002 → Feb 2003 | uveal melanoma | European Organisation for Research and Treatment of Cancer - EORTC | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NA17-A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00036816 ↗ |
| Modality | Vaccine | “Patients receive vaccination with NA17-A and melanoma differentiation peptides” NCT00036816 ↗ |
| Route | Other | “subcutaneously and intradermally” NCT00036816 ↗ |
| Route | Subcutaneous | “subcutaneously and intradermally” NCT00036816 ↗ |